JP2002502375A5 - - Google Patents

Download PDF

Info

Publication number
JP2002502375A5
JP2002502375A5 JP1998550524A JP55052498A JP2002502375A5 JP 2002502375 A5 JP2002502375 A5 JP 2002502375A5 JP 1998550524 A JP1998550524 A JP 1998550524A JP 55052498 A JP55052498 A JP 55052498A JP 2002502375 A5 JP2002502375 A5 JP 2002502375A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998550524A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002502375A (ja
Filing date
Publication date
Priority claimed from US08/858,343 external-priority patent/US6130221A/en
Application filed filed Critical
Publication of JP2002502375A publication Critical patent/JP2002502375A/ja
Publication of JP2002502375A5 publication Critical patent/JP2002502375A5/ja
Ceased legal-status Critical Current

Links

JP55052498A 1997-05-19 1998-05-19 脳アミロイドーシスを治療するための薬物 Ceased JP2002502375A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/858,343 1997-05-19
US08/858,343 US6130221A (en) 1997-03-05 1997-05-19 Pharmaceutical agents that impede the initiation and progression of primary and secondary DMS disruptions
PCT/US1998/010218 WO1998052898A1 (en) 1997-05-19 1998-05-19 Pharmaceutical agents for the treatment of cerebral amyloidosis

Publications (2)

Publication Number Publication Date
JP2002502375A JP2002502375A (ja) 2002-01-22
JP2002502375A5 true JP2002502375A5 (enExample) 2005-12-08

Family

ID=25328087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP55052498A Ceased JP2002502375A (ja) 1997-05-19 1998-05-19 脳アミロイドーシスを治療するための薬物

Country Status (7)

Country Link
US (2) US6130221A (enExample)
EP (2) EP1930308A1 (enExample)
JP (1) JP2002502375A (enExample)
AU (1) AU743845B2 (enExample)
CA (1) CA2290818A1 (enExample)
DE (1) DE69838785D1 (enExample)
WO (1) WO1998052898A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525339A (en) * 1986-08-27 1996-06-11 Dms Pharmaceutical Inc. Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
GB9911802D0 (en) * 1999-05-20 1999-07-21 Merck Sharp & Dohme Therapeutic combination
KR20070049251A (ko) 1999-10-27 2007-05-10 타녹스 인코퍼레이티드 조직 인자 길항제 및 그의 사용 방법
EP1829535A3 (en) * 1999-10-27 2007-10-24 Tanox, Inc. Tissue factor antagonists and methods of use thereof
AU2001253597A1 (en) * 2000-04-12 2001-10-30 Minerva Biotechnologies Corporation Treatment of neurodegenerative disease
US20020160988A1 (en) * 2001-02-20 2002-10-31 Israel Institute For Biological Research Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof
US7544681B2 (en) 2001-09-27 2009-06-09 Ramot At Tel Aviv University Ltd. Conjugated psychotropic drugs and uses thereof
JP2005535565A (ja) * 2002-03-04 2005-11-24 ナイモックス コーポレーション アルツハイマー病の症状を治療することが可能な化合物を決定する際に有用なスフェロン構成要素、並びに該構成要素から産生される治療および動物モデル
US7514407B2 (en) * 2002-03-04 2009-04-07 Nymox Corporation Spheron component peptides and pharmaceutical compositions
MX2009000641A (es) 2006-07-17 2009-02-12 Univ Ramot Conjugados que comprenden un farmaco sicotropico o un agonista de gaba y un acido organico y su uso en el tratamiento del dolor y otros desordenes del cns.
MX2012006566A (es) 2009-12-09 2012-11-29 Univ Ramot Metodo para mejorar las funciones cognoscitivas.
CA2789654A1 (en) 2010-02-24 2011-09-01 Ramot At Tel-Aviv University Ltd. Crystalline forms of the tri-mesylate salt of perphenazine-gaba and process of producing the same
WO2012038963A1 (en) * 2010-09-22 2012-03-29 Ramot At Tel-Aviv University Ltd. An acid addition salt of a nortriptyline-gaba conjugate and a process of preparing same
CN103896729A (zh) * 2012-12-28 2014-07-02 北大方正集团有限公司 一种制备4-氯双苯氯甲烷的方法
CN114341100A (zh) 2019-08-28 2022-04-12 联合利华知识产权控股有限公司 用于亮肤的新型化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL93018C (enExample) * 1957-10-22
US3060242A (en) * 1958-10-01 1962-10-23 Dow Chemical Co Aralkyl ether
US4540564A (en) * 1982-05-18 1985-09-10 University Of Florida Brain-specific drug delivery
ES8308553A1 (es) * 1982-06-17 1983-09-01 Ferrer Int "procedimiento de obtencion de nuevos derivados de piperazina".
BG41728A1 (en) * 1984-12-28 1987-08-14 Ninov Crystal form of 1- benzhydryl- 4- adyl- piperazine dihydrochloride and method for its preparation
US5231170A (en) * 1986-08-27 1993-07-27 Paul Averback Antibodies to dense microspheres
US4919915A (en) * 1987-03-03 1990-04-24 Paul Averback Method for detecting the ability to prevent red-to-green congophilic birefringence
US4816416A (en) * 1986-08-27 1989-03-28 Paul Averback Microspheric bodies for use in screening therapies for Azheimer's disease and related conditions
US5280032A (en) * 1989-02-14 1994-01-18 Toyama Chemical Co., Ltd. 1,2-ethanediol derivative and salt thereof, process for producing the same, and cerebral function-improving agent comprising the same

Similar Documents

Publication Publication Date Title
JP2000507042A5 (enExample)
JP2001524208A5 (enExample)
JP2002507282A5 (enExample)
JP2000509912A5 (enExample)
JP2000509942A5 (enExample)
JP2000510751A5 (enExample)
JP2001521530A5 (enExample)
JP2002508774A5 (enExample)
JP2000507369A5 (enExample)
JP2001523289A5 (enExample)
JP2000507433A5 (enExample)
JP2000510793A5 (enExample)
JP2000508022A5 (enExample)
JP2000515265A5 (enExample)
JP2000508680A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2000510247A5 (enExample)
JP2000510969A5 (enExample)
JP2002504941A5 (enExample)
JP2000508836A5 (enExample)
JP2000508102A5 (enExample)
JP2000509818A5 (enExample)
JP2001518873A5 (enExample)